AI Insights · Timothy · October 2024
Top 5 iOS Medical Apps in Africa Q3 2024
Explore the performance of the top 5 medical apps on iOS in Africa during Q3 2024, highlighting trends in downloads, revenue, and active users.
In the third quarter of 2024, the landscape of medical apps on iOS in Africa showcased diverse performance trends across the top five applications. According to data from Sensor Tower, here is a detailed look into the weekly downloads, revenue, and active user trends of these apps.
Elezaby, developed by Awfar Market in Egypt, experienced a fluctuating trend in weekly downloads. Starting at approximately 4K downloads in early July, the numbers gradually declined, reaching around 2.3K by mid-September, before slightly recovering to 2.7K by the end of the quarter.
Vezeeta - Doctors & Pharmacy from DrBridge maintained a consistent download rate throughout the quarter, hovering around 1.6K weekly downloads. The app's weekly revenue varied, peaking at $166 in early August, with a noticeable dip in early September to $22. Active users started at 4.1K in early July, slightly decreasing to 3.2K by late September.
The Pregnancy + | Tracker App by Philips Digital UK Limited saw a dynamic trend in weekly downloads, with a peak of 1.6K in mid-August. The app's weekly revenue showed fluctuations, starting at $266 in early July and ending at $247 by September's close. Active users remained robust, starting at 32.3K and closing the quarter at 34K.
Netcare displayed a stable download pattern, averaging around 1K weekly downloads, although active user data was unavailable.
Finally, Drug eye index recorded a gradual decline in downloads, starting at 1.1K in early July and tapering to 732 by the end of September. Active user data was not provided for this app.
These insights from Sensor Tower highlight the varied engagement and monetization strategies among leading medical apps in Africa, reflecting the diverse needs and preferences of users in the region. For more detailed insights and analytics, visit Sensor Tower.